首页> 外国专利> Process for the preparation of pharmaceutical compositions containing pirfenidone in the form of sustained release tablets and its application in the regression of human chronic renal failure, breast capsule contracture and liver fibrosis

Process for the preparation of pharmaceutical compositions containing pirfenidone in the form of sustained release tablets and its application in the regression of human chronic renal failure, breast capsule contracture and liver fibrosis

机译:含有吡非尼酮持续释放片剂形式的药物组合物的制备方法及其在人类慢性肾衰竭,乳腺囊膜挛缩和肝纤维化中的应用

摘要

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-± and anti-TGF-²1 action for the treatment of hepatic fibrosis.
机译:本发明涉及一种制备缓释片剂形式的药物组合物的方法,该药物组合物包含600毫克至2400毫克的吡非尼酮(PFD),使得该药物在延长的12小时内可被生物利用。从管理开始数小时。这样,药物吡非尼酮的抗纤维化和抗炎作用得以优化。此外,与吡非尼酮的其他药物形式相比,本发明具有口服给药的优点和更高的治疗功效,并且其在退行于原发性肾小球硬化的慢性肾衰竭中的治疗应用中。在人类植入乳房植入物后观察到的减少和/或消退乳房荚膜挛缩的有害作用方面,它具有更好的活性,并且对治疗具有重要的抗TNF-±和抗TGF-²1作用肝纤维化。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号